Alumis Inc.
Alumis is a U.S. biopharmaceutical company developing targeted medicines for immune-mediated and inflammatory diseases. Its research includes orally administered small-molecule approaches designed to modulate signaling pathways involved in autoimmune conditions. The company pursues therapeutic opportunities in dermatology and systemic immune disorders, supported by translational science and clinical development capabilities. Alumis is based in the San Francisco Bay Area and is listed on Nasdaq under ALMS. The company is classified here by its durable research focus rather than the current phase or outcome of any particular investigational program.
Company at a glance
Corporate information
- Company entity
- Alumis Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.alumis.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq: ALMS
oral targeted immune modulators · small molecules
autoimmune diseases · dermatology · immunology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Alumis is a U.S. biopharmaceutical company developing targeted medicines for immune-mediated and inflammatory diseases. Its research includes orally administered small-molecule approaches designed to modulate signaling pathways involved in autoimmune conditions. The company pursues therapeutic opportunities in dermatology and systemic immune disorders, supported by translational science and clinical development capabilities. Alumis is based in the San Francisco Bay Area and is listed on Nasdaq under ALMS. The company is classified here by its durable research focus rather than the current phase or outcome of any particular investigational program.
Business, technology & evidence
- SecuritiesNasdaq: ALMS
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Alumis Inc. ↗Alumis Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.